SLC30A9

Across TCGA pan-cancer cohorts, SLC30A9 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SLC30A9’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC30A9 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC30A9 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and KIRP are the cancer types where SLC30A9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC30A9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.804	<.001	10	view →
KIRC	Male	III,IV	−0.794	<.001	10	view →
KIRP	Male	III,IV	−0.966	<.001	9	view →
LIHC	All	All	+0.587	<.001	7	view →
BRCA	All	II,III,IV	+0.382	<.001	6	view →
CHOL	Male	All	+1.529	<.001	5	view →
LUAD	Male	All	+0.334	.005	2	view →
PRAD	All	All	+0.247	.036	2	view →
STAD	All	II,III,IV	+0.300	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SLC30A9–THCA

Open the THCA breakdown →